Operating Room

Henan’an, China

Operating Room

Henan’an, China
SEARCH FILTERS
Time filter
Source Type

New Market Research Reports Title "Global Hybrid Operating Room Market To Reach Worth USD 9.7 Bn By 2022: Credence Research" Has Been Added to Credenceresearch.com Report Database. San Jose, CA, April 20, 2017 --( Browse the full report Hybrid Operating Room Market: Growth, Future Prospects and Competitive Analysis, 2016-2022 report at http://www.credenceresearch.com/report/hybrid-operating-room-market Market Insights Hybrid operating rooms are extremely complex working environments where a large team of surgeons, interventionalists, nurses, anesthesiologists, and technicians need to work seamlessly together. A hybrid OR (Operating Room) is an alternative to conventional OR equipped with advanced medical imaging systems and devices supporting high quality interventional imaging and minimally invasive surgeries. North America held the largest regional market, accounting for the market share of over 37.3% in 2015, and is anticipated to dominate the global hybrid operating room market during the forecast period of 2016 to 2022. Rising number of hybrid operating room facilities and higher acceptance of technology are the key factors driving the North America hybrid operating room market. Asia Pacific is expected to grow at a highest growth rate during the focus period, due to rising medical tourism in the region, growing medical investments and healthcare infrastructure in Asia Pacific. Browse All Reports of This Category @ http://www.credenceresearch.com/industry/medical-devices-market Among the devices types, intraoperative diagnostic devices held the largest share in the global hybrid operating room market due to its wider application in the cardiovascular and neurosurgery. Moreover, rising minimally invasive surgeries would further enhance the application of intraoperative diagnostic devices driving the market further. The therapeutic application held the largest share in the global hybrid operating room market. The cardiovascular surgeries dominated the therapeutic application segment owing to the rise in the prevalence of cardiovascular diseases worldwide. The diagnostic imaging is anticipated to exhibit fastest growth rate in the hybrid operating room market. Rising number of minimally invasive surgery and robotic surgery to drive the diagnostic imaging market. Hospitals held the largest share in the end user segment of the global hybrid operating room market. Rising number of hospitals coming up with hybrid operating room is the major factor driving the hybrid operating room market. Clinics are expected to be the fastest growing end user segment in the global hybrid operating room market. Blog URL - http://www.mobilecomputingtoday.co.uk/4193/global-hybrid-operating-room-market-reach-worth-usd-9-7-2022-rising-demand-minimally-invasive-surgery-drive-market-credence-research/ About Credence Research: Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task. For More Information, Visit: Credence Research Media Contact Company Name: Credence Research Contact Person: Chris Smith, Designation: Global Sales Manager Phone: 1-800-361-8290 Address: 105 N 1st ST #429, San Jose, CA 95103 E-mail: sales@credenceresearch.com San Jose, CA, April 20, 2017 --( PR.com )-- According to the latest report published by Credence Research, Inc. “Hybrid Operating Room Market – (Device Type - Operating Tables, Lighting Systems, Surgical Beams, Surgical Imaging Displays, Intraoperative Diagnostic Devices and Operating Room Communication Systems; Application Type - Therapeutic: Cardiovascular Surgeries, Neurosurgery, Thoracic Surgery, Biopsy, Orthopedic Surgeries, Laparoscopic Surgeries, Emergency Care And Other Surgeries, Diagnostics: Fluoroscopy, Digital Subtraction Angiography, And 3D C-Arm Computer Tomography; End User – Hospitals, Clinics, Medical Research Institute And Ambulatory Surgical Centers) :Market Growth, Future Prospects and Competitive Analysis, 2016-2022,” the market was valued at USD 3.4 Bn in 2015, and is expected to reach USD 9.7 Bn by 2022, expanding at a CAGR of 16.1% from 2016 to 2022.Browse the full report Hybrid Operating Room Market: Growth, Future Prospects and Competitive Analysis, 2016-2022 report at http://www.credenceresearch.com/report/hybrid-operating-room-marketMarket InsightsHybrid operating rooms are extremely complex working environments where a large team of surgeons, interventionalists, nurses, anesthesiologists, and technicians need to work seamlessly together. A hybrid OR (Operating Room) is an alternative to conventional OR equipped with advanced medical imaging systems and devices supporting high quality interventional imaging and minimally invasive surgeries. North America held the largest regional market, accounting for the market share of over 37.3% in 2015, and is anticipated to dominate the global hybrid operating room market during the forecast period of 2016 to 2022. Rising number of hybrid operating room facilities and higher acceptance of technology are the key factors driving the North America hybrid operating room market. Asia Pacific is expected to grow at a highest growth rate during the focus period, due to rising medical tourism in the region, growing medical investments and healthcare infrastructure in Asia Pacific.Browse All Reports of This Category @ http://www.credenceresearch.com/industry/medical-devices-marketAmong the devices types, intraoperative diagnostic devices held the largest share in the global hybrid operating room market due to its wider application in the cardiovascular and neurosurgery. Moreover, rising minimally invasive surgeries would further enhance the application of intraoperative diagnostic devices driving the market further.The therapeutic application held the largest share in the global hybrid operating room market. The cardiovascular surgeries dominated the therapeutic application segment owing to the rise in the prevalence of cardiovascular diseases worldwide. The diagnostic imaging is anticipated to exhibit fastest growth rate in the hybrid operating room market. Rising number of minimally invasive surgery and robotic surgery to drive the diagnostic imaging market.Hospitals held the largest share in the end user segment of the global hybrid operating room market. Rising number of hospitals coming up with hybrid operating room is the major factor driving the hybrid operating room market. Clinics are expected to be the fastest growing end user segment in the global hybrid operating room market.Blog URL - http://www.mobilecomputingtoday.co.uk/4193/global-hybrid-operating-room-market-reach-worth-usd-9-7-2022-rising-demand-minimally-invasive-surgery-drive-market-credence-research/About Credence Research:Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.For More Information, Visit: Credence ResearchMedia ContactCompany Name: Credence ResearchContact Person: Chris Smith,Designation: Global Sales ManagerPhone: 1-800-361-8290Address: 105 N 1st ST #429, San Jose,CA 95103E-mail: sales@credenceresearch.com Click here to view the list of recent Press Releases from Credence Research


Despite increasing unit sales, increased competitiveness within the total patient monitoring market has had a negative impact on market growth. The entry of low cost foreign competition has been especially disruptive. However, the long-term prospects remain positive as demand for quality patient monitoring solutions will enable unit sales growth to outpace pricing pressure. Philips Healthcare is the leading competitor in the Australian patient monitoring market. The company competes in the multi-parameter vital sign monitoring market, wireless telemetry, pulse oximetry and fetal/neonatal monitoring markets. Their IntelliVue™ and SureSigns™ product lines range from low to high-acuity and have flexible product designs ranging from extremely compact to portable bedside units. GE Healthcare is the second leading competitor in the Australian patient monitoring market. GE offers an extensive product line that not only includes a range of low- to high-acuity monitoring devices, but also telemetry devices and networking solutions. Their product lines include the CARESCAPE™ B series and new B40™ patient monitors which can feed into the CARESCAPE™ central stations and mobile viewers to access patient information. Additional competitors in the Australia patient monitoring market include Dräger Medical, Medtronic, Mindray, Nihon Kohden, Natus Medical, Compumedics, Welch Allyn, Spacelabs Healthcare, Nonin and Smiths Medical among others. More on the patient monitoring device market in Australia can be found in a series of reports published by iData Research entitled the Australia Market Report Suite for Patient Monitoring Equipment. The suite covers reports on the following markets: multi-parameter vital signs monitoring, wireless ambulatory telemetry monitoring, telehealth, electromyogram monitoring, electroencephalogram monitoring, fetal and neonatal monitoring, pulse oximetry and blood pressure monitoring devices. The iData report series on patient monitoring devices covers the U.S., China, Australia, India, Japan, South Korea and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about patient monitoring device market data, register online or email us at info@idataresearch.net for an Australia Market Report Suite for Patient Monitoring Equipment brochure and synopsis. iData Research (www.idataresearch.com) is an international market consulting research firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Ophthalmics, Vascular Access, Laparoscopy, Urology, Gynecology, Endoscopy, Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more. We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/philips-and-ge-healthcare-lead-the-australia-patient-monitoring-equipment-market-due-to-the-adoption-of-less-invasive-more-accessible-patient-centric-device-configurations-300464048.html


The ASP decline is reinforced by competition among discount and value companies. However, the moderate growth rate of the U.S. dental implant industry has spurred the development and acceptance of technologies that facilitate dental implant placement and restoration. In turn, these technological advancements will further drive dental implant replacement rates. Additionally, technological advancements incorporated into dental software suites are set to drive sales, especially software that falls under premium brands. However, downward price pressure and the market entry of low-cost competitors will continue to offset gains in unit sales, resulting in moderate market values. The market has been restructuring, with discounted and value brands gaining popularity in the market. Generic and imitation abutments are growing more acceptable. Instrument kits are increasingly being given away. Treatment planning software is now bundled to help retain loyal customers. Discounted surgical guides are growing more prevalent. These market limiters have largely impacted market value and revenue potential in the overall U.S. market. The dental implant fixtures and final abutments market in the U.S. is largely controlled by three main companies: Nobel Biocare, Straumann and Dentsply Sirona. In addition to their current dominance in the market, they are also very active with ongoing acquisitions to further secure their leading positions. The leading competitors have also been able to maintain their ranking through a history of brand loyalty. The dental market is dominated by specialists such as periodontists and oral surgeons, who generally prefer premium brands. As a consequence, the premium companies are expected to maintain their dominance in upcoming years. As discount and value brands continue to emerge on the market, premium leaders are expected to continually lose market share. However, the market leaders have engaged in price cutting and bundling of large-scale purchases to remain competitive. Additional competitors in the U.S. dental implant fixtures market include Zimmer Biomet, BioHorizons, Implant Direct and MIS Implants among others. More on the dental implant market in the U.S. can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Dental Implant Fixtures and Final Abutments. The suite covers reports on the following markets: dental implant fixtures, final abutments, dental implant instrument kits, treatment planning software and surgical guides. The iData report series on dental implants covers the U.S., Argentina, Brazil, Mexico, China, Australia, Japan, South Korea and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about dental implant market data, register online or email us at info@idataresearch.net for a U.S. Market Report Suite for Dental Implant Fixtures and Final Abutments brochure and synopsis. iData Research (www.idataresearch.com) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Ophthalmics, Vascular Access, Laparoscopy, Urology, Gynecology, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more. We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nobel-biocare-straumann-dentsply-sirona-lead-us-dental-implant-fixtures-market-despite-pricing-pressure-from-low-cost-competitors-300464649.html


News Article | May 11, 2017
Site: globenewswire.com

CLEVELAND, May 11, 2017 (GLOBE NEWSWIRE) -- Mercury Biomed, a company developing a novel approach to managing core body temperature, announces it has won a non-dilutive Phase I Small Business Technology Transfer (STTR) grant through the National Institute of General Medical Sciences (NIGMS) for $225,000. The award (R41GM119871) will enable Mercury to accelerate commercialization of its first device, a disruptive solution for warming patients in the peri-operative environment. “Managing core body temperature safely and effectively in surgical procedures remains a big challenge, and Mercury’s air-free patient warming solution is designed for physicians and hospitals transitioning to value-based care and alternative payment models,” explains Brian Patrick, Mercury Co-Founder. Fifty three million patients undergo general anesthesia procedures each year and run the risk of life-threatening complications due to rapid reduction of core body temperature in the Operating Room. Warming patients during surgery has become standard of care, but Mercury’s approach is vastly different and considerably smarter than existing alternatives. Mercury’s WarmSmart system, in contrast to alternative methods, works in-concert with the body’s intrinsic thermoregulatory function to noninvasively warm the body core. WarmSmart is physiologically more efficient, less intrusive to the surgical field, easy-to-use, and eliminates the risk of surgical site infection associated with current forced-air warming devices. The global market for patient temperature management solutions is $2.5 billion per year. "Mercury is deeply appreciative of the assistance provided by the NIH and NIGMS through this STTR program," said Brad Pulver, CEO of Mercury Biomed. "Our mission is to provide the smartest, safest, and most clinically effective solution to help hospitals and surgeons who, in a growing number of cases, are required to accept financial responsibility for patient outcomes. This award expedites our time to market and allows us to continue our rapid progress and initial success toward this goal.” WarmSmart was developed from research conducted at The University of Texas at Austin. Professor Ken Diller, Inventor, Principal Investigator, and Mercury’s Chief Science Officer commented, “An award from this highly competitive STTR program is a testimony to the importance of improving safety and surgery outcomes, and our disruptive discovery for the field of human temperature management. The support of the NIH is validating to our efforts and will be instrumental in translating our technology from my bio heat transfer lab to commercial application." Based on the results achieved in Phase I and the scientific and technical merit and commercial potential of Mercury’s project, an additional potential $1.5M in non-dilutive funds may be awarded in Phase II.  During Phase II, Mercury would begin its second pivotal clinical trial with its partner, the Cleveland Clinic, where Drs. Daniel Sessler and Andrea Kurz, along with Dr. Wilton Levine (Mass General) will oversee Mercury’s clinical efforts. The grant is Mercury’s second major non-dilutive funding victory, as it was previously funded by the Ohio Third Frontier program, placing Mercury in rare company as a winner of both awards. About Mercury Biomed: Based in Cleveland, Ohio, Mercury Biomed, LLC is commercializing its proprietary Smart Temperature Management System™ technology, a breakthrough non-invasive and holistic approach to cooling and warming patients when and where it matters most. Founded in 2015, the company is led by top scientific experts and entrepreneurs in the field of therapeutic temperature management. Mercury Biomed’s WarmSmart product is currently in clinical trials and is targeted for a 2018 launch, pending FDA 510(k) clearance.  www.mercurybiomed.com About the National Institutes of Health (NIH) STTR & SBIR Programs: The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are designed to award federal research grants to small businesses conducting biomedical research. The goal of these Programs is to spur technological innovation leading to commercialization of novel innovative medical technologies to improve public health. Both Programs share this common goal, but differ somewhat in eligibility and research execution criteria. The NIH STTR and SBIR Programs are highly competitive, as reflected in the following award data statistics for Phase I STTR awards for fiscal years 2007-2016 available at https://sbir.nih.gov/statistics/award-data. For more information about the NIH STTR and SBIR Programs, please go to https://sbir.nih.gov/.


NEWPORT BEACH, CA--(Marketwired - May 9, 2017) - ORHub, Inc. ( : ORHB), a software company established as the 'Operating Room Hub' for surgery information control, is expanding its existing cloud-based platform and has scheduled pilot tests of its beta module for sterilization processing in the operating room in mid to late Q2. With over 51 million surgeries performed annually in the U.S., ORHub's platform addresses a vast market of care providers looking for ways to save time and money through the surgical process. ORHub provides valuable data that enables care providers to track and monitor inventory, compare costs, and identify financial impacts in the operating room at the point of surgery via data integration, pre-populated and non-duplicated information, and comparative insights. Through collaboration with current customers, ORHub has identified a significant opportunity to improve data flow management for the sterilization of implant trays. As the volume of surgeries in the U.S. continues to grow, tracking and management of multiple sterile trays per surgery is a critical link in the overall value chain for perioperative activities. "There is no greater need for efficient sterilization than in the operating room, where efficiency is paramount. The ORHub platform harnesses the power of big data to provide pre and post-operative data that transforms surgical resource management," says ORHub CEO Colt Melby. ORHub's revolutionary platform is currently being used in the operating room of two major hospitals in California. As recently announced, the Company has successfully collected data from 500 surgeries and is now responding to customer requests to build on this success and expand the data collected by its existing platform. "The perioperative department using our 'Operating Room Hub' has engaged to save even more time and reduce costs by addressing non-value added activities in the Sterile Processing Department. Our customers are key factors in our ability to help identify user needs and drive value-based opportunities in the $3 trillion health care market. This module shows the robustness of our user-centered design and the focus we have on value creation for our customers," says ORHub Chief Technology Officer Wesley Mitchell. ORHub's new module features a data network overlay that links valuable information within the sterilization processing department. Previously, this information had to be manually generated or siloed in multiple distributed systems. With ORHub's easy-to-use barcode scanning capability, care providers and sales reps have access to touchpad functionality and the opportunity to measure outcomes and cost-effectiveness at a case level. The end result is time and money saved, along with improved patient care. "We want to add capabilities for great support of the perioperative department and tray management. Our ability to focus on standards like GS1 and HIBC barcodes will help automate manual receiving and tracking of trays across the lifecycle of the case. As we evolve our services, we expect to drive analytics and deep learning capabilities to improve workflow variance and delays resulting from tray logistics issues. The case level information will help hospitals control costs and provide value-based outcomes to their patients," says Mitchell. ORHub is a cloud-based software platform focused on delivering value-based medicine in surgical care. The company enables all parties involved in surgical care to work together to organize, deliver, measure and reimburse in a single uniform process. This allows for significant decreases in cost and improvement in outcomes by eliminating inefficiencies, duplication of effort, and errors and omissions that result from siloed processes in software and poor handoffs from one part of the care process to another. The need for ORHub is clear. Health care comprises more than 17% of US GDP at over $3 trillion per year. With costs rising every year due to an aging population and more expensive treatments, providers are under severe pressure to become more efficient and reduce costs from payers who are aggressively reducing reimbursements and finally moving away from fee-for-service and toward performance-based reimbursement. ORHub enables providers to thrive in this new environment by addressing the single largest segment of health care, which is surgical care. ORHub replaces numerous legacy systems with a 360 degree system that is focused on tracking cost from diagnosis to discharge centered on treating a patient for a specific condition. ORHub has offices in Phoenix, Arizona; Newport Beach, California; and Bellevue, Washington. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the Company believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, it can give no assurances that its expectations will be attained. Such statements are inherently uncertain, and actual results and activities may differ materially from those estimated or projected. Certain factors that can affect the Company's ability to achieve its anticipated results include, among others, uncertainties inherent in the development of a new software product business.


News Article | May 11, 2017
Site: globenewswire.com

CLEVELAND, May 11, 2017 (GLOBE NEWSWIRE) -- Mercury Biomed, a company developing a novel approach to managing core body temperature, announces it has won a non-dilutive Phase I Small Business Technology Transfer (STTR) grant through the National Institute of General Medical Sciences (NIGMS) for $225,000. The award (R41GM119871) will enable Mercury to accelerate commercialization of its first device, a disruptive solution for warming patients in the peri-operative environment. “Managing core body temperature safely and effectively in surgical procedures remains a big challenge, and Mercury’s air-free patient warming solution is designed for physicians and hospitals transitioning to value-based care and alternative payment models,” explains Brian Patrick, Mercury Co-Founder. Fifty three million patients undergo general anesthesia procedures each year and run the risk of life-threatening complications due to rapid reduction of core body temperature in the Operating Room. Warming patients during surgery has become standard of care, but Mercury’s approach is vastly different and considerably smarter than existing alternatives. Mercury’s WarmSmart system, in contrast to alternative methods, works in-concert with the body’s intrinsic thermoregulatory function to noninvasively warm the body core. WarmSmart is physiologically more efficient, less intrusive to the surgical field, easy-to-use, and eliminates the risk of surgical site infection associated with current forced-air warming devices. The global market for patient temperature management solutions is $2.5 billion per year. "Mercury is deeply appreciative of the assistance provided by the NIH and NIGMS through this STTR program," said Brad Pulver, CEO of Mercury Biomed. "Our mission is to provide the smartest, safest, and most clinically effective solution to help hospitals and surgeons who, in a growing number of cases, are required to accept financial responsibility for patient outcomes. This award expedites our time to market and allows us to continue our rapid progress and initial success toward this goal.” WarmSmart was developed from research conducted at The University of Texas at Austin. Professor Ken Diller, Inventor, Principal Investigator, and Mercury’s Chief Science Officer commented, “An award from this highly competitive STTR program is a testimony to the importance of improving safety and surgery outcomes, and our disruptive discovery for the field of human temperature management. The support of the NIH is validating to our efforts and will be instrumental in translating our technology from my bio heat transfer lab to commercial application." Based on the results achieved in Phase I and the scientific and technical merit and commercial potential of Mercury’s project, an additional potential $1.5M in non-dilutive funds may be awarded in Phase II.  During Phase II, Mercury would begin its second pivotal clinical trial with its partner, the Cleveland Clinic, where Drs. Daniel Sessler and Andrea Kurz, along with Dr. Wilton Levine (Mass General) will oversee Mercury’s clinical efforts. The grant is Mercury’s second major non-dilutive funding victory, as it was previously funded by the Ohio Third Frontier program, placing Mercury in rare company as a winner of both awards. About Mercury Biomed: Based in Cleveland, Ohio, Mercury Biomed, LLC is commercializing its proprietary Smart Temperature Management System™ technology, a breakthrough non-invasive and holistic approach to cooling and warming patients when and where it matters most. Founded in 2015, the company is led by top scientific experts and entrepreneurs in the field of therapeutic temperature management. Mercury Biomed’s WarmSmart product is currently in clinical trials and is targeted for a 2018 launch, pending FDA 510(k) clearance.  www.mercurybiomed.com About the National Institutes of Health (NIH) STTR & SBIR Programs: The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are designed to award federal research grants to small businesses conducting biomedical research. The goal of these Programs is to spur technological innovation leading to commercialization of novel innovative medical technologies to improve public health. Both Programs share this common goal, but differ somewhat in eligibility and research execution criteria. The NIH STTR and SBIR Programs are highly competitive, as reflected in the following award data statistics for Phase I STTR awards for fiscal years 2007-2016 available at https://sbir.nih.gov/statistics/award-data. For more information about the NIH STTR and SBIR Programs, please go to https://sbir.nih.gov/.


News Article | May 11, 2017
Site: globenewswire.com

CLEVELAND, May 11, 2017 (GLOBE NEWSWIRE) -- Mercury Biomed, a company developing a novel approach to managing core body temperature, announces it has won a non-dilutive Phase I Small Business Technology Transfer (STTR) grant through the National Institute of General Medical Sciences (NIGMS) for $225,000. The award (R41GM119871) will enable Mercury to accelerate commercialization of its first device, a disruptive solution for warming patients in the peri-operative environment. “Managing core body temperature safely and effectively in surgical procedures remains a big challenge, and Mercury’s air-free patient warming solution is designed for physicians and hospitals transitioning to value-based care and alternative payment models,” explains Brian Patrick, Mercury Co-Founder. Fifty three million patients undergo general anesthesia procedures each year and run the risk of life-threatening complications due to rapid reduction of core body temperature in the Operating Room. Warming patients during surgery has become standard of care, but Mercury’s approach is vastly different and considerably smarter than existing alternatives. Mercury’s WarmSmart system, in contrast to alternative methods, works in-concert with the body’s intrinsic thermoregulatory function to noninvasively warm the body core. WarmSmart is physiologically more efficient, less intrusive to the surgical field, easy-to-use, and eliminates the risk of surgical site infection associated with current forced-air warming devices. The global market for patient temperature management solutions is $2.5 billion per year. "Mercury is deeply appreciative of the assistance provided by the NIH and NIGMS through this STTR program," said Brad Pulver, CEO of Mercury Biomed. "Our mission is to provide the smartest, safest, and most clinically effective solution to help hospitals and surgeons who, in a growing number of cases, are required to accept financial responsibility for patient outcomes. This award expedites our time to market and allows us to continue our rapid progress and initial success toward this goal.” WarmSmart was developed from research conducted at The University of Texas at Austin. Professor Ken Diller, Inventor, Principal Investigator, and Mercury’s Chief Science Officer commented, “An award from this highly competitive STTR program is a testimony to the importance of improving safety and surgery outcomes, and our disruptive discovery for the field of human temperature management. The support of the NIH is validating to our efforts and will be instrumental in translating our technology from my bio heat transfer lab to commercial application." Based on the results achieved in Phase I and the scientific and technical merit and commercial potential of Mercury’s project, an additional potential $1.5M in non-dilutive funds may be awarded in Phase II.  During Phase II, Mercury would begin its second pivotal clinical trial with its partner, the Cleveland Clinic, where Drs. Daniel Sessler and Andrea Kurz, along with Dr. Wilton Levine (Mass General) will oversee Mercury’s clinical efforts. The grant is Mercury’s second major non-dilutive funding victory, as it was previously funded by the Ohio Third Frontier program, placing Mercury in rare company as a winner of both awards. About Mercury Biomed: Based in Cleveland, Ohio, Mercury Biomed, LLC is commercializing its proprietary Smart Temperature Management System™ technology, a breakthrough non-invasive and holistic approach to cooling and warming patients when and where it matters most. Founded in 2015, the company is led by top scientific experts and entrepreneurs in the field of therapeutic temperature management. Mercury Biomed’s WarmSmart product is currently in clinical trials and is targeted for a 2018 launch, pending FDA 510(k) clearance.  www.mercurybiomed.com About the National Institutes of Health (NIH) STTR & SBIR Programs: The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are designed to award federal research grants to small businesses conducting biomedical research. The goal of these Programs is to spur technological innovation leading to commercialization of novel innovative medical technologies to improve public health. Both Programs share this common goal, but differ somewhat in eligibility and research execution criteria. The NIH STTR and SBIR Programs are highly competitive, as reflected in the following award data statistics for Phase I STTR awards for fiscal years 2007-2016 available at https://sbir.nih.gov/statistics/award-data. For more information about the NIH STTR and SBIR Programs, please go to https://sbir.nih.gov/.


News Article | May 11, 2017
Site: globenewswire.com

CLEVELAND, May 11, 2017 (GLOBE NEWSWIRE) -- Mercury Biomed, a company developing a novel approach to managing core body temperature, announces it has won a non-dilutive Phase I Small Business Technology Transfer (STTR) grant through the National Institute of General Medical Sciences (NIGMS) for $225,000. The award (R41GM119871) will enable Mercury to accelerate commercialization of its first device, a disruptive solution for warming patients in the peri-operative environment. “Managing core body temperature safely and effectively in surgical procedures remains a big challenge, and Mercury’s air-free patient warming solution is designed for physicians and hospitals transitioning to value-based care and alternative payment models,” explains Brian Patrick, Mercury Co-Founder. Fifty three million patients undergo general anesthesia procedures each year and run the risk of life-threatening complications due to rapid reduction of core body temperature in the Operating Room. Warming patients during surgery has become standard of care, but Mercury’s approach is vastly different and considerably smarter than existing alternatives. Mercury’s WarmSmart system, in contrast to alternative methods, works in-concert with the body’s intrinsic thermoregulatory function to noninvasively warm the body core. WarmSmart is physiologically more efficient, less intrusive to the surgical field, easy-to-use, and eliminates the risk of surgical site infection associated with current forced-air warming devices. The global market for patient temperature management solutions is $2.5 billion per year. "Mercury is deeply appreciative of the assistance provided by the NIH and NIGMS through this STTR program," said Brad Pulver, CEO of Mercury Biomed. "Our mission is to provide the smartest, safest, and most clinically effective solution to help hospitals and surgeons who, in a growing number of cases, are required to accept financial responsibility for patient outcomes. This award expedites our time to market and allows us to continue our rapid progress and initial success toward this goal.” WarmSmart was developed from research conducted at The University of Texas at Austin. Professor Ken Diller, Inventor, Principal Investigator, and Mercury’s Chief Science Officer commented, “An award from this highly competitive STTR program is a testimony to the importance of improving safety and surgery outcomes, and our disruptive discovery for the field of human temperature management. The support of the NIH is validating to our efforts and will be instrumental in translating our technology from my bio heat transfer lab to commercial application." Based on the results achieved in Phase I and the scientific and technical merit and commercial potential of Mercury’s project, an additional potential $1.5M in non-dilutive funds may be awarded in Phase II.  During Phase II, Mercury would begin its second pivotal clinical trial with its partner, the Cleveland Clinic, where Drs. Daniel Sessler and Andrea Kurz, along with Dr. Wilton Levine (Mass General) will oversee Mercury’s clinical efforts. The grant is Mercury’s second major non-dilutive funding victory, as it was previously funded by the Ohio Third Frontier program, placing Mercury in rare company as a winner of both awards. About Mercury Biomed: Based in Cleveland, Ohio, Mercury Biomed, LLC is commercializing its proprietary Smart Temperature Management System™ technology, a breakthrough non-invasive and holistic approach to cooling and warming patients when and where it matters most. Founded in 2015, the company is led by top scientific experts and entrepreneurs in the field of therapeutic temperature management. Mercury Biomed’s WarmSmart product is currently in clinical trials and is targeted for a 2018 launch, pending FDA 510(k) clearance.  www.mercurybiomed.com About the National Institutes of Health (NIH) STTR & SBIR Programs: The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are designed to award federal research grants to small businesses conducting biomedical research. The goal of these Programs is to spur technological innovation leading to commercialization of novel innovative medical technologies to improve public health. Both Programs share this common goal, but differ somewhat in eligibility and research execution criteria. The NIH STTR and SBIR Programs are highly competitive, as reflected in the following award data statistics for Phase I STTR awards for fiscal years 2007-2016 available at https://sbir.nih.gov/statistics/award-data. For more information about the NIH STTR and SBIR Programs, please go to https://sbir.nih.gov/.


(PRLEAP.COM)– According to a new series of reports on the U.S. market for diagnostic ophthalmic devices by iData Research ( www.idataresearch.com ), manufacturers are introducing new technologies into fundus camera systems, including angiography and fluorescent dye tracking. As a result, total fundus camera unit sales are moderately growing. Table mounted sales for both imaging modalities are being driven by the replacement of older technology. The natural growth of the market associated with the increase in the elderly populations which is directly correlated with the incidence of ocular disease.This market includes mydriatic and non-mydriatic fundus cameras. Each of the segments are further divided into table mounted and handheld devices. The persistent growth of the market is driven by the prevalence of age-related ocular conditions, such as glaucoma and macular degeneration. However, the average selling price for the total fundus camera market will depreciate over the next several years. This decrease can partially be attributed to the influx of inexpensive handheld devices and the competitive nature of the market that is being seen across all fundus camera segments. As a result, the significantly less expensive handheld mydriatic market is strongly outpacing the unit growth of the established table mounted market. Furthermore, the table mounted market is losing ground to combination devices which incorporate fundus cameras into other ophthalmic equipment."Traditionally the non-mydriatic fundus camera has been the choice of optometrists for several reasons; it is less expensive, the additional capabilities were not used as much by optometrists, and the need for chemical pupil dilation was an inconvenience for patients post procedure," explains Jeffrey Wong, Strategic Analyst Manager at iData Research. "This is beginning to change as the increased range of capabilities offered by mydriatic cameras can also be a competitive advantage for an optometrist seeking patients."Topcon is the leading competitor in the U.S. fundus camera market. The company manufactures table mounted fundus cameras for both the mydriatic and non-mydriatic market. As part of the table mounted non-mydriatic fundus cameras Topcon manufactures the TRC-NW8®, TRC-NW8F® and the TRC-NW400®. In the mydriatic market Topcon manufactures the TRC-50DX® Series.Carl Zeiss Meditec is the second leading competitor in the U.S. fundus camera market. The company manufactures five fundus cameras, and participates in all segments of this market. Their latest fundus camera, the VISUCAM® 224 has a 24-megapixel sensor for high resolution images. Additional competitors in the U.S. fundus camera market include Canon and Kowa among others.More on the fundus camera market in the U.S can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Diagnostic Ophthalmic Devices . The suite covers reports on the following markets: Ophthalmic coherence tomography, fundus cameras, data management systems, slit lamps, perimeters, tonometers, autorefractors/keratometers, binocular indirect ophthalmoscopes, ophthalmic ultrasound devices, wavefront abberometers, corneal topographers and optical biometers.The iData report series on ophthalmic devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about ophthalmic device market data, register online or email us at info@idataresearch.net for a U.S. Market Report Suite for Diagnostic Ophthalmic Devices brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Ophthalmics, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Vascular Access, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Endoscopy, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Dental Operatory Equipment and more.We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.


Global Operating Room Equipment Market by Products, Geography, Trends and Forecast to 2021, New Report by iHealthcareAnalyst, Inc. Operating Room Equipment Market by Equipment Used in Operating Room (Operating Room Integration Systems, Lights, Tables, Surgical Booms and Surgical Imaging Display Systems) and Forecast 2017-2021 Maryland Heights, MO, May 09, 2017 --( Browse Operating Room Equipment Market by Equipment Used in Operating Room (Operating Room Integration Systems, Lights, Tables, Surgical Booms and Surgical Imaging Display Systems) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/operating-room-equipment-market/ The global operating room equipment market report estimates the market size (Revenue USD million - 2014 to 2021) for market segments based on equipment used in operating room and forecasts growth trends (CAGR% - 2017 to 2021). The global operating room equipment market report estimates the market size (Revenue USD million – 2014 to 2021) for market segments based on equipment used in operating room (operating tables, operating room lights, surgical booms, operating room integration systems and surgical imaging displays) and forecasts growth trends (CAGR% – 2017 to 2021). The global operating room equipment market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global operating room equipment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. Major players operating in the global operating room equipment market and included in this report are Getinge Group, Steris Corporation, Stryker Corporation, Berchtold Corporation, Skytron, LLC, TRUMPF GmbH + Co. KG, Karl Storz GmbH & Co. KG, Eschmann Equipment, Mizuho OSI and NDS Surgical Imaging, LLC. 1. Product Type 1.1. Operating Room Integration Systems 1.2. Operating Room Lights 1.3. Operating Tables 1.4. Surgical Booms 1.5. Surgical Imaging Displays 2. Company Profiles 2.1. Berchtold Corporation 2.2. Eschmann Equipment 2.3. Getinge Group 2.4. Karl Storz GmbH & Co. KG 2.5. Mizuho OSI 2.6. NDS Surgical Imaging, LLC 2.7. Skytron, LLC 2.8. Steris Corporation 2.9. Stryker Corporation 2.10. TRUMPF GmbH Co. KG To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/operating-room-equipment-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, May 09, 2017 --( PR.com )-- Within hospitals, surgical operations are carried out in a sterile environment in an operating room (OR) or operating theater or operating suite which consists of operating room integration systems, lights, tables, surgical booms and surgical imaging display systems. The rising concerns about reduction in healthcare spending and achieving accurate surgical outcomes, healthcare providers across the globe are focusing on enhancing operating room efficiency, while minimizing the required resources and related costs. Some of the factors that are expected to drive market growth during the forecast period include gradual increase in number of ambulatory surgical centers worldwide, increasing demand for hybrid operating rooms and technological advancement in safe and cost-effective operating procedures.Browse Operating Room Equipment Market by Equipment Used in Operating Room (Operating Room Integration Systems, Lights, Tables, Surgical Booms and Surgical Imaging Display Systems) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/operating-room-equipment-market/The global operating room equipment market report estimates the market size (Revenue USD million - 2014 to 2021) for market segments based on equipment used in operating room and forecasts growth trends (CAGR% - 2017 to 2021). The global operating room equipment market report estimates the market size (Revenue USD million – 2014 to 2021) for market segments based on equipment used in operating room (operating tables, operating room lights, surgical booms, operating room integration systems and surgical imaging displays) and forecasts growth trends (CAGR% – 2017 to 2021). The global operating room equipment market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global operating room equipment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.Major players operating in the global operating room equipment market and included in this report are Getinge Group, Steris Corporation, Stryker Corporation, Berchtold Corporation, Skytron, LLC, TRUMPF GmbH + Co. KG, Karl Storz GmbH & Co. KG, Eschmann Equipment, Mizuho OSI and NDS Surgical Imaging, LLC.1. Product Type1.1. Operating Room Integration Systems1.2. Operating Room Lights1.3. Operating Tables1.4. Surgical Booms1.5. Surgical Imaging Displays2. Company Profiles2.1. Berchtold Corporation2.2. Eschmann Equipment2.3. Getinge Group2.4. Karl Storz GmbH & Co. KG2.5. Mizuho OSI2.6. NDS Surgical Imaging, LLC2.7. Skytron, LLC2.8. Steris Corporation2.9. Stryker Corporation2.10. TRUMPF GmbH Co. KGTo request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/operating-room-equipment-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com

Loading Operating Room collaborators
Loading Operating Room collaborators